(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Curl Up With Some Hot Chocolate And Watch Mighty Car Mods Explore Japan In A Honda City Turbo II - 2ISS astronaut evacuation shouldn't interfere with upcoming Artemis 2 moon mission, NASA chief says
- 3German foreign minister backs abandoning EU's unanimity principle
- 4The Main 20 Gaming Control center Ever
- 5Going with Children: Tips for Tranquil Family Get-aways
- US bishops officially ban gender-affirming care at Catholic hospitals
- Vehicle Lovers' Decision: Purchase A Reasonable Vehicle
- Flash flooding causes highways to close to and from Eilat
- Famous Network programs in Europe and America
- 8 Espresso Bean Starting points All over the Planet
- Minneapolis ICE shooting live updates: Protests continue over agent's killing of Renee Nicole Good; Walz puts National Guard on standby
- The most effective method to Shake Hands Expertly: A Bit by bit Guide
- New Jordan security fence could be done in early 2028
- These 2 moon rovers used cameras and lasers to hunt for simulated water ice — and one looks like WALL-E
